T he molecular millennium has bestowed researchers with the essential tools to identify the underlying genetic substrates for thousands of genetic disorders, most of which are rare and follow mendelian inheritance patterns. The genetic bases of potentially lethal and heritable cardiomyopathies and cardiac channelopathies, including hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), left ventricular noncompaction, arrhythmogenic right ventricular cardiomyopathy (ARVC), long-QT syndrome (LQTS), short-QT syndrome (SQTS), catecholaminergic polymorphic ventricular tachycardia (CPVT), Brugada syndrome (BrS), and familial atrial fibrillation, have been identified and are now better understood.
Marked genetic heterogeneity and clinical heterogeneity are hallmark features of these disorders, with multiple genes and allelic variants subserving their underlying pathogenic mechanisms. To date, thousands of gene mutations at the single-nucleotide level have been discovered for this group of divergent cardiovascular disorders of the heart. Most mutations represent pathogenic disease-causing mutations only discovered in disease cohorts, whereas others are common or rare genetic polymorphisms identified in disease and in health that may or may not provide the precise pathogenic substrate. Genetic testing for several of these heritable cardiomyopathies and channelopathies has made its transition from discovery through translation, with clinical genetic tests now available commercially.
The purpose of the present review is to provide the reader with a foundational understanding of genetic testing in clinical practice. Here, we will present some general principles of genetic testing, the need for careful interpretation of genetic testing results, the importance of genetic counseling, and some points on the ethical, legal, and societal implications of genetic testing. We will conclude by reviewing the state of clinical genetic testing for 4 of the principal cardiomyopathies/channelopathies: HCM, LQTS, CPVT, and BrS.
General Principles of Genetic Testing Mutation Types in Human Genetic Disease
Genes contain an encrypted genetic message for the assembly of polypeptides or proteins that serve the biological function of the cell. Polypeptides or proteins are polymers of linear repeating units called amino acids. The amino acid-encoding sequences within genes are called exons, and between the exons are intervening DNA sequences called introns, which are not a part of the genetic code and are removed during splicing. The assembly of a polypeptide is directed by a triplet genetic code or codon (3 consecutive bases), of which there are 64 codons that encode for either 20 distinct amino acids or the termination (stop codon) of protein assembly. Each codon is decoded sequentially to give a specific sequence of amino acids that are covalently linked through peptide bonds and ultimately make up a protein.
The DNA of the human genome is highly stable from generation to generation but not immutable. Instead, it is vulnerable to an array of different types of germline (heritably transmitted) and somatic mutations. In general, mutations can be classified into 3 categories: genome mutations, chromosome mutations, and gene mutations. 1 Genome mutations involve the abnormal segregation of chromosomes during cell division (for example, trisomy 21 [Down syndrome]). Chromosome mutations involve the structural breakage and rearrangement of chromosomes during cell division or major deletions or insertions of portions of a particular chromosome (for example, chromosome 22q11.2 microdeletion syndrome). Finally, gene mutations involve nucleotide alterations that disrupt the normal function of a single gene product. This review will focus mainly on genetic testing for gene mutations. Such single-gene mutations are classified into 3 primary categories: Single-nucleotide substitutions, deletions, and insertions.
Single-Nucleotide Substitutions
Single-nucleotide substitutions represent the most common type of pathogenic mutation for the various genetic heart diseases to be reviewed here, accounting for approximately two thirds of the pathogenic mutations. If a single-nucleotide substitution occurs in the coding region (exon), the result may be either a synonymous (silent) mutation whereby the new codon still encodes the same amino acid ( Figure 1 ) or a nonsynonymous mutation whereby the altered codon encodes for a different amino acid or terminates further protein Figure 1 . Nucleotide substitutions. Compared with the depicted normal DNA, amino acid (single-letter abbreviation) sequence, and resulting peptide sequence are examples of nucleotide substitutions and deletion mutations. The amino acids of the peptide sequence are color coded to represent their unique biophysical properties, where yellow represents nonpolar hydrophobic amino acids, green is polar hydrophilic, pink is negatively charged acidic residues, and blue represents positively charged basic amino acid residues. A nucleotide change resulting in a new codon that encodes for (A) the same amino acid as the normal sequence is a silent mutation, (B) a different amino acid is a missense mutation, and (C) a termination codon is a nonsense mutation. Illustrated in panel D is a deletion of a single nucleotide (G) that results in a shift of the open reading frame of the transcript, thus representing a frameshift mutation. Note assembly (ie, introduces a premature stop codon). The term missense mutation is used to specify a single-nucleotide substitution that disrupts the open reading frame and replaces the normal (wild type) amino acid with a different one ( Figure  1 ). Importantly, a missense mutation may or may not result in a functionally perturbed protein that leads to a disease phenotype. The functional consequence of a missense mutation may depend on the differences in biochemical properties between the amino acids that are being substituted or the location in the protein at which the exchange occurs. A nonsense mutation refers to a nonsynonymous single-nucleotide substitution that mutates a codon that encodes 1 of 20 amino acids to 1 of the 3 stop codons (Figure 1) . A nonsense mutation results in a truncated (shortened) gene product at the location of the new stop codon. The functional effects could range from no appreciable difference to functional lethality (a nonfunctioning protein), depending again on where in the protein a nonsense mutation occurs.
Intronic (noncoding) base substitutions may also result in an altered gene product. The normal process by which intronic sequences are excised to give a mature protein-encoding transcript is reliant on specific nucleotide sequences located at the intron/exon (acceptor site) and exon/intron (donor site) boundaries. Base substitutions within these highly conserved sequences can result in abnormal splicing. In some cases, entire exons can be skipped (deleted), or entire introns may be included in the mature transcript, most often resulting in a frameshift.
Insertions and Deletions
Gene mutations may also involve insertions and deletions of nucleotides that can be as small as a single-nucleotide insertion/deletion or as large as several hundred to several thousand nucleotides in length. Most of these insertions and deletions that occur in the exon alter the reading frame of translation at the point of the insertion/deletion and produce a new sequence of amino acids in the finished product, a frameshift mutation ( Figure 1 ). Many frameshift mutations often result in a different product length from the normal gene product by creating a new stop codon, which produces either a shorter or longer gene product depending on the location of the new stop codon. When a multiple of 3 nucleotides is either inserted or deleted, in-frame insertions and deletions result in single or multiple amino acids being removed or added without affecting the remainder of the transcript (Figure 1 ).
Mutation Nomenclature
The standard nomenclature for numbering nucleotides and codons within a gene begins with the A of the initiation, or start codon (ATG), representing nucleotide 1 and ATG as codon 1. 2 Generally, only consecutive nucleotides constituting the coding region of the gene are numbered. For an extensive review of mutation nomenclature, see www.hgvs.org/mutnomen or the article by den Dunnen and Antonarakis. 2 Universally accepted nomenclature exists for describing mutations/genetic variants at both the DNA and protein levels.
The DNA-level description of a nucleotide alteration begins with the affected nucleotide number(s) followed by the original nucleotide, the type of change (substitutions are designated as Ͼ, deletions as del, and insertions as ins), and the new nucleotide. For example, a single-nucleotide substitution of an A (alanine) to a G (guanine) at nucleotide position 100 would be written as 100 AϾG or 100 aϾg. A deletion of A at nucleotide 100 would be written as 100delA, and a single-nucleotide insertion of a C between nucleotides 100 and 101 would be written as 100_101insC. Intronic nucleotides are numbered relative to either the first or last nucleotide in the exon that precedes or follows the intron. When a nucleotide change occurs in the intron preceding the exon (ie, the acceptor splice site), the nucleotide position is considered a negative position relative to the first nucleotide of the exon. When the nucleotide change occurs in the intron that follows an exon (ie, donor splice site), the position would be a positive position relative to the last nucleotide of the exon. For example, the KCNQ1 exon 2, nucleotide substitution 477ϩ5 GϾA, results from a G-to-A substitution in the intron, 5 nucleotides after exon 2, where nucleotide 477 is the final nucleotide of exon 2. 3 The protein-level description of a nucleotide substitution begins with the original amino acid (using either the singleor 3-letter abbreviation for the amino acid, whereas an X or ter denotes a termination or stop codon) for which the affected codon encodes, followed by the codon number, then the amino acid for which the mutated codon (resulting from the nucleotide exchange) encodes. For example, a nucleotide alteration that results in the exchange of a methionine (M or Met) to a leucine (L or Leu) at codon 56 (a missense mutation) would be written as M56L or Met56Leu. A nucleotide substitution that results in tyrosine (Y or Tyr) being mutated to a stop codon (X or Ter) at codon 57 (a nonsense mutation) is indicated as Y57X or Tyr57Ter. A nucleotide substitution in which the new codon at position 58 does not specify a new amino acid (silent or synonymous mutation) would be written as Y58Y. A nucleotide substitution that alters normal splicing would be written as M159sp, where at position 159, methionine (M) is the last normal amino acid before the splicing error.
Nucleotide insertions and deletions may result in either in-frame or frameshift alterations in the transcript. An inframe deletion (del) of the methionine at position 56 would be written as M56del, and a deletion of both M56 and Y57 would be written as M56_Y57del. An in-frame insertion (ins) of a serine (S) between methionine at position 56 and tyrosine at 57 would be written as M56_Y57insS. Frameshift (fs) mutations as a result of either a deletion or insertion of nucleotides are generally written as the amino acid that is affected followed by fsX and then the codon number that precedes the new termination or stop codon (X). For example, Figure 1 (Continued) . how the sequence of amino acids has been altered from this point forward. Although not illustrated here, frameshift mutations as a result of a deletion or insertion of nucleotides often lead to a premature stop codon and thus a truncated protein.
As illustrated in panel E, the deletion of 3 nucleotides (GAC) produced an in-frame deletion of a single amino acid (aspartic acid; Asp) in the protein. The remaining amino acid sequence is unaltered. Three nucleotide insertions (not shown) can have a similar affect whereby an amino acid is inserted into the protein product.
M56fsX62 or M56fs ϩ5X represents a frameshift mutation in which methionine (M) at position 56 is the first amino acid that is frameshifted, followed by 5 additional frameshifted amino acids before the protein prematurely truncates with a new stop codon at position 62.
Genotyping Jargon
Inherited variation in the genome is the basis of human and medical genetics. Reciprocal forms of genetic information at a specific locus (location) along the genome are called alleles. An allele can refer to a segment of DNA or even a single nucleotide. The normal version of genetic information is often considered the wild-type, or normal, allele. The vast majority of the human genome represents a single version of genetic information. The DNA from one person is mostly made up of the same nucleotide sequence as another person's DNA; however, there are many small sections of sequence or even single nucleotides that differ from one individual to another. These normal variations at distinct loci in the DNA sequence are called polymorphisms. 1 Some polymorphisms are very common, whereas others represent rare genetic variants. In medical genetics, a diseasecausing mutation refers to a DNA sequence variation that represents an abnormal allele and is not found in the normal healthy population but exists only in the disease population and produces a functionally abnormal product. However, this definition presumes a depth of understanding of the presence or absence of a particular mutation among normal subjects and the production of a biologically perturbed protein. In general, a single-nucleotide substitution that occurs with a measurable frequency (ie, Ͼ0.5% allelic frequency) among a particular ethnic population is designated as a single-nucleotide polymorphism, whereas those single-nucleotide polymorphisms that occur less frequently than this threshold are termed mutations.
Unfortunately, this terminological distinction has probably brought about more confusion than clarity, because singlenucleotide polymorphisms do not necessarily have to be benign, and a mutation may not be pathogenic. In fact, single-nucleotide polymorphisms can represent functional, biological, and clinically relevant disease-or treatment-modifying biomarkers. In addition, a mutation (ie, a rare, Ͻ0.5% frequency variant) can be "just there, just rare, just because." 26 As will be detailed later, distinguishing pathogenic mutations from simply rare ones is critical to genetic test interpretation and presently represents genetic testing's Achilles' heel.
A person is said to be homozygous when he or she has a pair of identical alleles, 1 paternal (from father) and 1 maternal (from mother). When the alleles are different, then that person is said to be heterozygous for that particular allele. The term genotype refers to a person's genetic or DNA sequence composition at a particular loci, or at a combined body of loci, and the term phenotype refers to a person's observed clinical expression of disease in terms of a morphological, biochemical, or molecular trait. 4 Penetrance is the likelihood that a pathogenic mutation will have a discernible expression among a population of mutation-positive subjects. For example, a gene mutation with an ascribed penetrance of 75% means that 75% of those who possess that particular gene mutation will exhibit a measurable, diagnostic feature (phenotype) indicative of its presence, such as echocardiographic evidence of left ventricular hypertrophy in HCM or electrocardiographic (ECG) evidence of QT prolongation in LQTS. The vast majority of heritable cardiomyopathies and channelopathies are associated with disease-susceptibility genes characterized by incomplete penetrance. Expressivity refers to the level of phenotypic expression, and when the phenotypic manifestations of individuals who have the same genotype are diverse, the phenotype is said to exhibit variable expressivity. Reduced penetrance and variable expressivity create a significant challenge for the appropriate diagnosis, pedigree interpretation, and risk stratification of genetic disorders.
Genetic variants may be inherited (familial) or represent spontaneously derived (sporadic) de novo variants occurring for the first time in an individual. Variants/mutations are said to be germline if present in the gametes (sperm or ovum) or somatic if in cells other than gametes. Germline mutations may be transmitted to offspring, whereas somatic mutations cannot. Mosaicism refers to a condition in which different cells in the same individual have a different genetic makeup. For example, an individual may have a mutation occur within his or her gametes, but either not in other specific cell types at all or in limited numbers of other cells of the body (ie, in his sperm or her ovum [egg] but not in his or her peripheral blood lymphocytes). Germline or gonadal mosaicism is beginning to emerge as a recognized, albeit rare, pattern of transmission in some disorders, including LQTS. 5 Genetic disorders are characterized by their patterns of transmission within families. There are 4 basic modes: Autosomal dominant, autosomal recessive, X-linked dominant, and X-linked recessive. 1 These modes of inheritance are based primarily on 2 factors: (1) What type of chromosome (autosome or X chromosome) the gene is located on and (2) whether the disease phenotype is expressed only when both chromosomes have the abnormal allele (recessive) or if the phenotype can be expressed even when only 1 chromosome hosts the mutant allele (dominant). The majority of heritable cardiomyopathies and channelopathies are familial, rather than sporadic, and autosomal dominant rather than autosomal recessive.
Genetic Testing Methods

Biological Material Used
Typically, 5 to 15 mL of whole blood obtained from venipuncture placed in EDTA-containing tubes (purple top) is requested as the genomic DNA source for either research or clinic-based genetic testing. 4 For some genetic tests, a 50-L blood spot on a Guthrie DNA filter card may be a sufficient source for genomic DNA. 6 Although it may not always provide a sufficient amount of DNA for comprehensive genetic testing, DNA isolated from a buccal (mouth cheek) swab can be used for mutation-specific confirmatory testing of family relatives. Umbilical cord blood may be acquired at the time of birth for newborn screening. DNA derived from sperm or ovum may be helpful in assessments for gonadal mosaicism. For autopsy-negative sudden unexplained death cases, genetic testing can be completed on DNA isolated from blood from an EDTA-containing tube or from a piece of frozen ventricle myocardium tissue or tissue from any other organ (liver, spleen, thymus) with a high nucleus-to-cytoplasm ratio. 7 DNA from tissue in formalin or from paraffin-embedded tissue, however, remains an unreliable source and may yield a false-positive genetic test result. 8 Both research-based and clinical genetic testing typically require a signed and dated informed consent form to accompany the samples to be tested. Importantly, some clinical laboratories currently accept only certain sources of DNA for specific tests, usually venipuncture or buccal swabs.
General Techniques Used in Genetic Testing at the Single-Gene Level
In genetic testing, the elucidation of gene mutations usually involves the polymerase chain reaction (PCR) technique. PCR is used to amplify many copies of a specific region of DNA sequence within the gene of interest, defined by the location of uniquely designed PCR primers. Typically, 20 to 25 base pairs (bp) of forward and reverse single-stranded DNA oligonucleotide primers are designed to be complementary to reciprocal intronic DNA sequences that flank the exon of interest to produce PCR products, or amplicons, (200 to 400 bp in length) that contain the desired DNA sequence to be analyzed. It is important that primers be designed properly in this mutation detection process, because false-negatives secondary to poor primer design and possible allelic dropout can occur. 9 A well-optimized PCR reaction will yield millions of copies of only the specific sequence of interest. 10 Among research laboratories, PCR amplification is often followed by an intermediate mutation-detection platform, such as single-stranded conformational polymorphism, denaturing gradient gel electrophoresis, or denaturing highperformance liquid chromatography. The sensitivity of detection with these methods ranges from approximately 80% to 95% and is highly dependent on proper optimization of conditions. Failure to optimize correctly will result in mutation-detection failures. After identification of a possible abnormality, direct DNA sequencing must be used to determine the precise underlying DNA alteration(s). Review and comparison of the resulting sequence chromatograms and the published wild-type DNA and amino acid sequence for the gene or protein of interest will allow for determination of whether the underlying DNA change is protein altering and potentially pathogenic or a nonpathogenic normal variant.
In contrast, for most commercially available genetic tests, the intermediate mutation-detection platform is bypassed for direct DNA sequencing of all samples examined. Although this direct approach to mutational analysis is presently more expensive, its sensitivity, specificity, and speed for mutation detection are superior to the typical research-based platforms. Recent advances in DNA sequencing methodologies and technical instrumentation have resulted in rapid evolution of DNA sequencing capacity and genetic information output. For example, through the use of next-generation sequencing, massively parallel sequencing, and oligonucleotide hybridization chip-based technologies, the molecular interrogation of an individual's complete library of specific diseaseassociated protein-coding sequences in a single or a few reactions with remarkable cost-effectiveness 11, 12 is now available in a limited number of laboratories. At the current pace, it is conceivable that specific gene-panel testing for specific heritable diseases will become extinct by 2020, being replaced by comprehensive human genome testing.
Together, these techniques provide excellent precision and accuracy to detect both single-nucleotide substitutions that produce missense, nonsense, and splice-site mutations and small insertion/deletions; however, large whole-gene, multiple-exon, or single-exon deletions or duplications elude detection by this approach. Another technique, multipleligation probe analysis, however, enables identification of such large gene rearrangements. [13] [14] [15] Besides multipleligation probe analysis, other technologies for copy number variant detection exist.
Genetic Testing in a Research Versus Clinical Setting
Research studies are those in which patient samples are collected on the basis of study design and inclusion or exclusion criteria. Research-based genetic tests are performed principally for discovery purposes and the advancement of science, with direct benefit to the research subject as an ancillary feature, whereas commercial, clinical, fee-based genetic testing is a patient-centric test ordered by a referring physician based on his or her clinical index of suspicion and clinical objective to establish or refute a considered diagnosis, obtain further risk-stratifying information, and guide clinical decision making. The cost of research testing is generally covered by an investigator's research program. Research laboratories, in accordance with their institutional review board, may be granted permission to inform a study participant of their genetic test result. Importantly, research-derived test results are provided initially to the research subject rather than to his or her healthcare provider. When applicable, research laboratories typically quote research subjects 6 to 24 months as the time frame to expect to learn of a positive result from examination of established disease-susceptibility genes (if the known genes are even being examined) and, of course, an indefinite and indeterminate time frame when research testing is strictly focused on novel discovery. In some cases, several years elapsed after submission of a blood sample before the research participants were made the direct beneficiaries of the testing results. In some research settings, patients may never be informed of either a positive or negative genetic test result. Genetic testing in the research environment often relies on assays developed in-house rather than on commercially available kits approved by the Food and Drug Administration. 16 In the research setting, genetic tests are often available before their analytic and clinical validity are established. Furthermore, quality control mechanisms and "good laboratory practices" are not under the same strict guidelines and regulations as for a clinical diagnostic test.
In contrast, a clinical genetic test is a fee-based test performed with the intent to inform both the healthcare provider and patient of the test result with a definite diagnostic, prognostic, or therapeutic goal in mind. The charge for the clinical genetic test is generally based on the complexity of the test and is generally proportional to the amount of genetic material being scanned. In the United States, a clinical laboratory must be approved under the Clinical Laboratory Improvement Amendments and regulated by the Centers for Medicaid and Medicare Services. 17 To receive approval under the Clinical Laboratory Improvement Amendments, the testing laboratory must meet quality control and proficiency testing standards in accordance with "good laboratory practices." On-site inspections are conducted to ensure proper personnel qualifications, clinical testing procedures, and quality control measures and documentation.
Typically, the clinically available genetic test is a highthroughput, automated, direct DNA sequencing-based assay performed with 2-to 4-fold redundancy to maximize diagnostic accuracy. Unlike the research laboratory environment, the clinical laboratory is usually a highly ordered environment with personnel in specifically designated roles to ensure maximum efficiency and quality control measures for the genetic test. Rather than reporting results to the research participant after a long period of time, as with research testing efforts, results (both positive and negative) from the clinical genetic test are reported to the ordering physician in a written report within approximately 4 to 8 weeks for index case testing and within 2 to 4 weeks for mutation-specific confirmatory testing for family members.
Genetic testing for several cardiomyopathies and cardiac channelopathies has made the quantum leap from researchbased discovery and translation to the highly regulated clinical laboratory environment. Genetic testing for heritable cardiomyopathies and channelopathies has been recognized by leading cardiovascular societies throughout the world as clinically relevant. 18 Furthermore, in the United States, many Centers represent those listed on GeneTests.org as of May 2010 that offer fee-based clinical genetic testing. 20 The genes tested and methods used for each disorder will vary between centers. For more details and contact information for each center, see www.GeneTests.org.
third-party payers have begun to acknowledge their clinical utility and have implemented favorable reimbursement policies. For example, in April 2008, the Blue Cross Blue Shield Technology Evaluation Center concluded that LQTS genetic testing was no longer investigational. 19 
Clinically Available Genetic Testing for Cardiovascular Diseases
Once confined to the research laboratory, genetic testing for HCM, DCM, ARVC, LQTS, CPVT, and BrS-associated mutations has matured into clinically available diagnostic tests for physicians evaluating and treating patients with these diseases. An international index of clinically available genetic tests and testing centers is inventoried at GeneTests, a continually updated, publically funded, online medical genetics information resource (www.genetests.org) for physicians and other healthcare providers. 20 Table 1 These laboratories use a variety of technologies, including oligonucleotide hybridization chip-based methodology, traditional direct dideoxy DNA sequencing, and highthroughput "next-generation" or "massively parallel" sequencing. The analytic sensitivity of these tests is typically 95% to 100% for the detection of nucleotide substitutions and small insertion/deletion mutations. Some laboratories also currently offer multiple-ligation probe analysis for the detection of large gene rearrangements that would escape detection when standard DNA sequencing methodologies are used. Although most laboratories provide genetic testing for the most common susceptibility genes for each of the diseases, some laboratories offer genetic testing for even the rarest forms of each disorder (Tables 2 and 3) . Although some genetic test vendors comprehensively analyze the full protein-encoding region of each gene, others analyze only targeted regions of genes where mutations have been shown to reside.
Once a disease-causing mutation is identified within a proband, mutation-specific genetic testing is offered for family members. Where published, the index test ranges in price from approximately $3000 to $5500 (US), depending on the test, and mutation-specific confirmatory testing costs $100 to $900, depending on the genetic testing vendor. As indicated previously, the insurance reimbursement landscape is changing rapidly, with favorable coverage policies being adopted akin to the same evolutionary process that other genetic tests, such as for cystic fibrosis and breast cancer, have undergone.
Importantly, as discussed in the subsequent sections for each particular disorder, the anticipated yield from genetic testing is disease specific, ranging from a low of 25% to 30% for BrS genetic testing to a 75% yield for LQTS genetic testing. As such, patients with a robust, unequivocal clinical Rare is defined as Ͻ1% anticipated contribution to the syndrome. Note that the rare disease-susceptibility genes are indicated in alphabetical order. phenotype for their respective disorder who have a negative genetic test should at least be informed of ongoing research efforts and directed toward research centers that specialize in the study of their particular disorder. Continued genetic analysis on a research basis of well-phenotyped patient cohorts will allow for new gene discovery and continued enhancement, expansion, and refinement of genetic testing in clinical practice.
Potential Benefits and Indications for Genetic Testing
Genetic testing may provide clear diagnostic, prognostic, and therapeutic implications for some disorders. [21] [22] [23] Genetic testing may (1) offer diagnostic value for symptomatic individuals by elucidating the exact molecular basis for the disorder, (2) establish a definitive molecular diagnosis or disease prediction when the clinical evaluation for the disorder is inconclusive, (3) confirm or exclude the presence of a disease-causing mutation in presymptomatic family members/relatives with a family history of a genetic disorder, and (4) help personalize treatment recommendations and management of a patient's specific disorder by characterization of the precise genotype. 24, 25 Genetic testing may also provide carrier status for those concerned about recessively inherited disorders such as cystic fibrosis.
As an aside, the term "carrier" should not be used for the majority of the genetic heart diseases to be discussed in the following section. A carrier generally refers to someone who only carries a disease-susceptibility mutation but has no risk of expressing a phenotype associated with that particular pathogenic mutation. For the majority of the cardiomyopathies/channelopathies, a single mutated allele (autosomal dominant) is sufficient for disease expression, in contrast to cystic fibrosis. As such, a mutation-positive subject is not simply a carrier but potentially has risk for disease expression. For clarity, the term carrier should be reserved for autosomal recessive conditions and should not be used to describe patients with diseases such as HCM and LQTS.
As will be discussed in more detail in future sections of this review, specific indications for and utility of genetic testing vary depending on the disorder. For example, although a recommendation for universal neonatal genetic testing for LQTS would be utterly irresponsible, as would pre-sports participation HCM genetic testing, clinical suspicion and first-degree relative confirmatory testing are clear indications for genetic testing in these various disorders (Figure 2 ). Most importantly, rather than proceeding with shotgun-based genetic testing, clinical evaluation should be used to phenotypically guide genetic testing and provide specific indicators for which genetic test(s) to order. For illustrative purposes, Figure 3 provides an example of a workflow decision tree for possible indicators for genetic testing in the evaluation of a patient with exercise-induced syncope or cardiac arrest. Furthermore, the degree to which genetic testing contributes to the triad of diagnostic, prognostic, and therapeutic utility is also disease specific, with LQTS genetic testing contributing to the entire triad, whereas genetic testing for other diseases may be of diagnostic value only for the index case and his or her relatives (Figure 4 ).
Interpretation of Genetic Test Results: The "Variant of Uncertain/Unclear Significance" Issue
Because of the potential enormity and severe consequences surrounding the misdiagnosis and mismanagement of patients with these potentially lethal cardiac disorders, the clinical evaluation and management of a patient and family suspected of having genetic heart disease should be conducted under the supervision of a pediatric or adult cardiologist with specific expertise in heritable channelopathies/cardiomyopathies. 4 Owing to the issues associated with incomplete penetrance and variable expressivity, the genetic test result must be interpreted cautiously and incorporated into the overall diag- Rare is defined as Ͻ1% anticipated contribution to the syndrome. Note that the rare disease-susceptibility genes are indicated in alphabetical order. Although the disease genotypic subtype is provided in parentheses for these rare disease-susceptibility genes, we recommend annotating only the common genotypes with such a numeric designation and refer to the rare ones with their gene descriptor, such as AKAP9-LQTS rather than LQT11 and GPD1L-BrS rather than BrS2. nostic evaluation for these disorders. Even when a genetic variant has been published previously as a putative pathogenic mutation, assignment of a specific genetic variant as a true pathogenic disease-causing mutation still requires vigi-lant scrutiny. To be sure, genetic tests are fundamentally probabilistic tests rather than absolutely deterministic ones. To illustrate further, in contrast to rare, pathogenic LQTSassociated channel mutations present in Ͻ1 in 2500 persons (0.04%) and in 75% of clinically strong LQTS cases, comprehensive genetic testing of KCNQ1 (LQT1), KCNH2 (LQT2), and SCN5A (LQT3) for Ͼ1300 ostensibly healthy volunteers has demonstrated that approximately 4% of whites and up to 8% nonwhites host rare (Ͻ0.5% allelic frequency), nonsynonymous (amino acid altering) genetic variants in these cardiac channel genes. 26 Some of the variants observed in this healthy population may represent subclinical disease modifiers, whereas the vast majority must represent benign background genetic noise.
Although exposed for the LQTS genes, this observation of background nonpathogenic missense variants is not confined to this disorder, but likely extends throughout all of the heritable cardiomyopathies and channelopathies detailed here and may well extend to virtually every gene in the human genome. However, although there are currently Ͼ1500 clinically available genetic tests for various disorders, only for a handful of diseases is the signal-to-noise ratio regarding genetic variation known as it is for the major LQTSsusceptibility genes. For LQTS genetic testing, this effort has enabled a case-control mutational analysis of the properties and localization of case-associated mutations compared with the compendium of presumably innocuous variants. 26 Here, algorithms based on mutation location may assist in distinguishing pathogenic mutations from an otherwise rare variant of uncertain or unclear significance and perhaps allow for the assignment of an estimated probability of pathogenicity of each novel mutation identified within a specific gene. 26 This probabilistic rather than binary nature of genetic testing is depicted in Figure 5 , which shows that although rare nonsense, insertion/deletion, and splice-site mutations are highprobability LQTS-susceptibility mutations, the probability of pathogenicity for missense mutations is strongly predicated on location. For example, missense mutations that localize to the transmembrane-spanning/pore domains of the LQT1-and LQT2-associated potassium channels are high-probability disease mutations, whereas a similarly rare missense mutation that localizes to the domain I-II linker of the LQT3-associated sodium channel is absolutely uncertain (ie, a variant of uncertain or unclear significance). Without cosegregation or functional data, such a mutation has a point estimate for probability of pathogenicity of Ͻ50%, which necessitates that one use extreme caution when interpreting the genetic test.
Genetic Counseling
If the ordering cardiologist, heart rhythm specialist, or cardiomyopathy/channelopathy subspecialist lacks genetic expertise with regard to the particular disorder being considered, it is beneficial to have a master's-trained, board-certified genetic counselor, preferably with specialized training in cardiovascular genetics, as part of the team to be involved in the communication process with the patient concerning the implications of genetic testing and genetic test results. A genetic counselor may be instrumental in (1) collecting a family history comprising at least 3 to 4 generations; (2) providing information as to the clinical presentation of the disorder, mode of inheritance, and implications in family planning; (3) explaining the benefits, limitations, risk, availability, costs, and potential outcomes of genetic testing; and (4) discussing the possible psychosocial impact of these potentially lethal disorders with the patient and his or her family. 27, 28 
Ethical, Legal, and Societal Implications
Although benefits such as diagnostic certainty and greater awareness of prophylactic treatment and risk stratification may be achieved, genetic testing may also contribute to an increase in risk for depression, anxiety, guilt, stigmatization, discrimination, family conflict, and unnecessary or inappropriate use of risk-reducing strategies. 29 Therefore, it is imperative that patients be well informed on genetic testing implications, and they must not be coerced into providing a sample for genetic analysis. Full disclosure must be given as to the research or clinical intent of the genetic test, the results of the analysis, and who will have access to the results. 4 Genetic information must be considered private and personal information with the potential for mishandling. 30, 31 Confidential information disclosure to third parties, including insurance companies or employers, can have genetic discrim-inatory consequences for the patient. However, in May 2009, the Genetic Information Nondiscrimination Act (GINA) was signed into federal law, barring employers and health insurers from denying employment or insurance to a healthy individual on the basis of genetic test results. 32 Despite this welcomed advance, the law failed to extend discriminatory protection over either life insurance or disability insurance.
Genetic testing should be considered both a family and an individual experience. 29 Although genetic testing is performed on an individual's genetic material, both the individual's decision to undergo genetic testing and that individual's test results may have substantial implications for other family members, especially in sudden cardiac death-related disorders. However, under current practice anchored in the principle of autonomy, only the individual being tested or the legal guardian, if a minor, has to be informed of their genetic test results. The decision or responsibility to inform unsuspecting relatives of the potential for genetic predisposition for sudden cardiac death resides solely with that informed patient. 4
Genetic Testing for Specific Heritable Cardiomyopathies and Channelopathies
Cardiomyopathies and Channelopathies: Clinical Descriptions, Genetics, and Indications/Benefits of Genetic Testing
Although commercially available genetic testing exists for HCM, DCM, ARVC, left ventricular noncompaction, LQTS, SQTS, CPVT, and BrS, this review will focus on the 4 genetic cardiomyopathies/channelopathies (HCM, LQTS, CPVT, and BrS) for which the clinical utility is arguably the greatest at the present time. DCM and ARVC genetic testing is evolving rapidly, and although it is commercially available, genetic testing for DCM and ARVC is presently handicapped by low yields, unclear clinical impact apart from first-degree relative confirmatory mutation testing, and comparatively high background noise rates that make DCM and ARVC genetic test interpretations extremely challenging. Figure 5 . Probabilistic nature of LQTS genetic testing. Depicted are the 3 major ion channels causative for LQTS, with areas of probability of pathogenicity shown for mutations that localize to these respective areas. Although radical mutations have a Ͼ90% probability of being a true pathogenic mutation, the level of probability for missense mutations varies, depending on their location, for each channel protein. Missense mutations residing in red-shaded areas have a high probability (Ͼ80%) of being pathogenic, those in blue are possibly (51% to 80%) pathogenic, and those in yellow areas truly represent variants of uncertain/ unclear significance (Յ50% probability) clinically. 26 Hypertrophic Cardiomyopathy HCM is characterized as asymmetrical left ventricular hypertrophy in the absence of a clinically identifiable cause. HCM affects 1 in 500 people, but more important is the fact that it is the most common cause of premature sudden cardiac death in the young, especially young athletes. Clinically, HCM is viewed principally as a disease of incomplete penetrance and variable expressivity, because the clinical course varies extremely, ranging from an asymptomatic lifelong course to chest pain, exertion-related dyspnea, syncope, progressive exercise intolerance, or sudden death as the sentinel event occurring at any age. 28, [33] [34] [35] Morphologically, HCM may present with negligible to extreme hypertrophy, minimal to extensive fibrosis and myocyte disarray, and absent to severe left ventricular outflow tract obstruction. Distinct septal contours/morphologies such as reverse-curve, sigmoidal, and apical variant HCM have been identified. 33 HCM is inherited primarily in an autosomal dominant fashion.
The most common genetic subtype of HCM is sarcomeric or myofilament HCM, secondary to mutations in genes encoding for proteins of the thick and thin myofilaments of the cardiac sarcomere ( Table 2 ). The yield from HCM gene testing that involves the 8 or 9 established HCMsusceptibility genes for sarcomeric HCM ranges from 35% to 65% among several different international research cohorts of unrelated patients who met the clinically accepted definition of HCM. 21, 28, 36, 37 In addition, echocardiography may be used to guide genetic testing by providing an estimate of the a priori probability of a positive genetic test on the basis of morphological subtyping. 38 Of the 2 most common morphological subtypes of HCM, reverse septal curvature HCM or reverse-curve HCM and HCM with a sigmoidal ventricular septum or sigmoidal HCM, patients with reverse-curve HCM have an 80% chance of a positive genetic test, whereas only a minority of patients with sigmoidal HCM will test positive.
MYBPC3 and MYH7 are by far the 2 most common HCM-associated genes, with an estimated prevalence of 25% to 35% for each gene, and they account for the majority of positive research-based genetic tests. Additionally, genes encoding components of the cardiac Z-disc, calcium (Ca 2ϩ )handling, and regulatory proteins have been associated with HCM pathogenesis. Mutations in several genes encoding proteins responsible for cellular metabolic processes have been linked to unexplained left ventricular hypertrophy that can mimic the HCM phenotype. To date, hundreds of mutations have been identified in at least 27 putative HCMsusceptibility genes ( Table 2 ).
In terms of the diagnostic, prognostic, and therapeutic implications of genetic testing, HCM genetic testing contributes primarily to the diagnostic part of the triad and secondarily to prognosis and therapeutic impact (Figure 4) . Although a negative genetic test cannot "rule out" HCM, a positive genetic test may play an important role in distinguishing HCM from exercise-adaptive hypertrophy (so-called athlete's heart) or from HCM phenocopies such as Anderson-Fabry, glycogen (PRKAG2) and lysosomal (LAMP2) storage, mitochondrial, Noonan, and LEOPARD syndromes, for which there are definitive and alternative therapies distinct from HCM treatments. 35 Additionally, genetic testing of the proband may provide the diagnostic "gold standard" for his or her relatives. A positive genetic test would enable systematic scrutiny of an HCM-affected proband's relatives to identify those relatives who are mutation-positive irrespective of their currently manifest clinical phenotype, which would enable early detection and appropriate targeting of relatives for ongoing surveillance while dismissing those mutationnegative/phenotype-negative family members and thereby the need for regular cardiac evaluations and echocardiograms. Furthermore, chemoprevention may be possible in the future whereby strategies can be used to prevent or delay the onset of hypertrophy among those patients who are genotypepositive but hypertrophy-negative. Drawing from promising animal data, a randomized study called DiltiazEm Long-term In Genotype-positive Hypertrophic cardiomyopathy as preclinical Treatment (DELITE) that involves prophylactic diltiazem pharmacotherapy is under way for humans with mutation-positive/left ventricular hypertrophy-negative HCM. 39 Since the seminal observation in 1992, there has been much debate as to whether the genetic test result provides an independent risk factor for either degree of hypertrophy or susceptibility for sudden death. It has been 18 years since Watkins and colleagues noted that within families hosting particular MYH7 mutations, some mutations, like MYH7-R453C, were associated with a 50% mortality at 40 years, whereas other mutations appeared to confer normal longevity. 40 This observation set into motion the notion of malignant mutations and benign mutations. However, among unrelated patients, each discrete HCM-causative mutation is rare, and the previous genotype-phenotype associations may not hold firm. In fact, among the first 400 unrelated patients with HCM that we tested, only 3 possessed 1 of the mutations coined as malignant, and 7 patients had 1 of the benign mutations, of whom 4 had already undergone a surgical myectomy, 3 had a positive family history of premature sudden death, and 1 had received a heart transplant at the age of 16 years despite her benign form of HCM. 41, 42 Presently, great restraint must be exercised when one is tempted to make a prophylactic implantable cardioverter defibrillator decision based on the genetic test result. Instead, the current clinical evidence supports a prognostic mutation class effect whereby unrelated patients with a positive genetic test for sarcomeric HCM exhibit a more severe phenotype in terms of degree of hypertrophy, age at diagnosis, and likelihood to progress to end-stage disease than do clinically diagnosed HCM patients with a negative genetic test. 43, 44 However, it is not clear how this observation translates to the bedside in terms of therapeutic approach for the patient with sarcomeric/myofilament HCM (ie, a positive genetic test) compared with the patient with HCM with a negative genetic test.
Long-QT Syndrome
With prevalence as high as 1 in 2500 persons, 45 congenital LQTS comprises a distinct group of cardiac channelopathies characterized by delayed cardiac repolarization manifesting as QT prolongation on a resting 12-lead surface ECG in the setting of a structurally normal heart. Patients have an increased risk for syncope, seizures, and sudden cardiac death, usually precipitated by triggers such as physical exertion (swimming), emotion, or auditory stimuli (alarm clocks, door bells, etc) or during the postpartum period. 22, 23 Although typically, normal sinus rhythm returns spontaneously, resulting in an episode of torsadogenic syncope, 5% of untreated and unsuspecting LQTS individuals succumb to a fatal arrhythmia as their first event. As many as 20% of autopsy-negative sudden unexplained deaths 46 and 10% of sudden infant death syndrome (SIDS) deaths may be attributed to LQTS. 47 Like all the cardiac channelopathies discussed in the present review, incomplete penetrance and variable expressivity are hallmark features of LQTS.
LQTS is a genetically heterogeneous disorder most often inherited in an autosomal dominant manner (previously known as Romano-Ward syndrome). Rarely, LQTS presents as the recessive trait first described by Drs Jervell and Lange-Nielsen 47a and is characterized by a severe cardiac phenotype and sensorineural hearing loss. In addition, 5% to 10% of LQTS results from a spontaneous/sporadic germline mutation rather than familial inheritance. Hundreds of mutations have now been identified in 12 LQTS-susceptibility genes (Table 3) , with approximately 75% of clinically strong LQTS due to mutations in 3 genes that critically orchestrate the cardiac action potential of the ventricular myocytes: KCNQ1 (LQT1), KCNH2 (LQT2), and SCN5A (LQT3). 3, 22, 23 The remainder of genotype-positive LQTS stems from mutations in genes that encode either other cardiac channels, channel-interacting proteins, or structural membrane scaffolding proteins that modulate channel function. These minor LQTS-susceptibility genes associated with LQT4 through LQT12 contribute to Ͻ5% of LQTS.
The majority of LQTS-causing mutations are codingregion single-nucleotide substitutions or small insertions/ deletions. 3, 48, 49 However, recently, a few large gene rearrangements involving hundreds to thousands of nucleotides resulting in single or multiple whole-exon deletions/duplica-tions have been described. 13, 14 It is important to note that 20% to 25% of LQTS remains genetically elusive. Thus, continued genetic testing on a research basis of clinically strong yet genotype-negative (negative for LQT1 through LQT12) patients will be critical for novel gene discovery.
Phenotype-genotype associations may facilitate phenotype-directed genetic testing for LQTS. For example, swimming-and exertion-induced cardiac events strongly indicate mutations in KCNQ1, whereas auditory triggers and events that occur during the postpartum period should prompt suspicion for LQT2, and an event during sleep is associated with LQT3 ( Figure 6 ). 22,23,50 -54 In contrast, exercise-induced syncope in the setting of a normal corrected QT interval (QTc Ͻ 460 ms) should move suspicion away from concealed LQT1 and instead point toward a phenotypic mimicker of concealed LQT1, namely, CPVT. 55 Characteristic genesuggestive ECG patterns have been described previously. 22, 23 LQT1 is associated with a broad-based T wave, LQT2 with a low-amplitude notched or biphasic T wave, and LQT3 with a long isoelectric segment followed by a narrow-based T wave. These gene-suggestive ECG patterns may be helpful in guiding genetic testing; however, exceptions to these relatively gene-specific T-wave patterns exist, and due caution must be exercised in making a pre-genetic test prediction of the particular LQTS subtype. For example, the most common clinical mimicker of the LQT3-looking ECG is seen among patients with LQT1. The clinical management in the mindset of LQT3 for a patient who actually has LQT1 could prompt an unnecessarily aggressive recommendation to implant an internal cardioverter defibrillator as a prophylactic measure.
Genetic testing not only has significant diagnostic implications but also has prognostic and therapeutic implications in LQTS (Figure 4 ). For example, the underlying genetic basis heavily influences the response to standard LQTS pharmacotherapy (␤-blockers), because ␤-blockers are extremely protective in LQT1 patients but not as protective for Figure 6 . Genotype-phenotype correlations in long-QT syndrome. Seventy-five percent of clinically strong long-QT syndrome is due to mutations in 3 genes (35% to KCNQ1, 30% to KCNH2, and 10% to SCN5A) that encode for ion channels that are critically responsible for orchestration of cardiac action potential. Genotype-phenotype correlations have been observed, including swimming/exertion and LQT1, auditory triggers/postpartum period and LQT2, and sleep/rest and LQT3. Bar graphs represent genotypephenotype data from Schwartz et al. 53 Also illustrated is the relative genespecific effectiveness of ␤-blocker therapy, which shows that ␤-blockers are extremely protective in LQT1 patients, moderately protective in LQT2, and somewhat protective for those with LQT3. Late sodium current blockers like mexiletine and ranolazine may provide additional protection in LQT3. patients with either LQT2 or LQT3 ( Figure 6 ). 22, 23, 56 However, targeting the pathological, LQT3-associated late sodium current with agents such as mexiletine, flecainide, ranolazine, or propranolol may represent a gene-specific therapeutic option for LQT3 ( Figure 6 ). 22, 23, 57, 58 In addition, intragenotype risk stratification has been realized for LQT1 and LQT2 on the basis of mutation type, mutation location, and cellular function. 59 -64 For example, patients with LQT1 transmembrane-localizing missense mutations have a 2-fold greater risk of an LQT1-triggered cardiac event than LQT1 patients with C-terminal-localizing mutations. Trumping location, LQT1 patients with mutations that result in a greater degree of ion channel loss of function at the cellular in vitro level (ie, dominant negative) have a 2-fold greater clinical risk than those with mutations that damage the biology of the channel less severely (haploinsufficiency). Patients with LQT2 secondary to pore-region mutations have a longer QTc, a more severe clinical manifestation of the disorder, and significantly more arrhythmiarelated cardiac events occurring at a younger age than those LQT2 patients with nonpore mutations. 59 Additionally, LQT2 patients with mutations that involve the transmembrane pore region have the greatest risk for cardiac events, those with frameshift/nonsense mutations in any region have an intermediate risk, and those with missense mutations in the C-terminus have the lowest risk for cardiac events. 64 In 2010, LQTS genotyping fully satisfies the triad in terms of diagnostic (move toward or away from diagnosis in the index case, gold standard rule in/rule out in family members), prognostic (both between and within genotypes), and therapeutic (LQT1 patients clinically approached with a fundamentally distinct treatment plan from that for LQT3 patients, for example) impact.
From a clinical test standpoint, any patient with a suspected clinical LQTS diagnosis should be offered clinical genetic testing even when the QTc is unequivocally prolonged (ie, Ͼ500 ms) and the clinical diagnosis is not in doubt. As indicated above, such genotyping additionally stratifies risk and guides treatment decisions. Furthermore, genotyping of such an index case has a 75% likelihood of yielding the index case's possible or probable LQTS-associated mutation, and if positive, genotyping of appropriate relatives in concentric circles of first-degree relatedness can definitively rule in or rule out the genetic diagnosis regardless of its phenotypic expression in terms of symptoms or QT interval. To be sure, when genetic LQTS has been established in a family, a screening ECG is insufficient to assess the presence or absence of the familial LQTS genetic trait. Additionally, LQTS clinical genetic testing may also be warranted for patients with unexplained exertional syncope or drug-induced QT prolongation/torsade de pointes who do not meet full LQTS diagnostic criteria and are left with a rendered diagnosis of possible or borderline LQTS. Here, genetic testing could help upgrade the diagnosis from clinically equivocal to genetically probable. Alternatively, a negative genetic test effectively rules out 75% of congenital LQTS, and such a result could provide an independent objective test to help the LQTS specialist mount evidence to move away from this contemplated diagnosis.
Catecholaminergic Polymorphic Ventricular Tachycardia
CPVT is another heritable arrhythmia syndrome that classically manifests with exercise-induced syncope or sudden death. 55, 65, 66 CPVT is associated with a normal resting ECG with possible bradycardia and U waves and is clinically suspected on the basis of history and documentation of significant ventricular ectopy, including bidirectional ventricular tachycardia, during either treadmill or catecholamine stress testing. Like LQTS, CPVT is generally associated with a structurally normal heart; however, CPVT is more lethal, with a positive family history of juvenile (Ͻ40 years) sudden cardiac death for Ͼ30% of CPVT individuals and up to 60% in families hosting mutations in RYR2. 65 In addition, 15% of autopsy-negative sudden unexplained death may be attributed to CPVT. 7, 46 Like LQT1, swimming is a potentially lethal arrhythmia-precipitating trigger in CPVT. In fact, both LQT1 and CPVT have been shown to underlie several cases of unexplained drowning or near-drowning involving previously healthy young swimmers.
CPVT stems from genetic mutations in genes that encode components of the macromolecular intracellular Ca 2ϩ release channel complex within the sarcoplasmic reticulum of the cardiocyte (Figure 7) . Mutations in the RYR2-encoded cardiac ryanodine receptor 2/calcium release channel represent the most common genetic subtype of CPVT (CPVT1), accounting for approximately 50% to 60% of CPVT cases (Table 3) . 55, 65 The 105-exon-containing RYR2 gene encodes for one of the largest proteins in the human proteome and the largest ion channel, comprising 4967 amino acids. Although there do not appear to be any specific mutation hotspots, there are 3 regional hotspots or domains where unique mutations reside (Figure 7) . 55 This observation has led to the possibility of targeted genetic testing of RYR2 rather than a comprehensive 105-exon analysis (Figure 7) . However, currently, there is no consensus or clear definition of the most appropriate targeted RYR2 scan. Presently, two thirds of detectable RYR2 mutations localize to 16 exons, whereas all of the currently published mutations are confined to 45 of the 105 translated exons of RYR2. 55 Although Ͼ90% of RYR2 mutations discovered to date represent missense mutations, as many as 5% of unrelated CPVT patients have large RYR2 gene rearrangements consistent with large, whole-exon deletions that would not be detected by standard direct DNA sequencing technology, similar to what has been observed in LQTS. 55 A rare autosomal recessive subtype of CPVT is mediated by mutations in CASQ2-encoded calsequestrin 2 (CPVT2). 67 Strikingly, nearly one third of possible or atypical LQTS (QTc Ͻ480 ms) cases with exertion-induced syncope have also been identified as positive for an RYR2 mutation (Figure 7 ), 55 and accordingly, a clinical presentation of exercise-induced syncope and a QTc Ͻ460 ms should always prompt first consideration of CPVT rather than so-called concealed or normal-QT-interval LQT1. In fact, it has been reported that nearly 30% of patients with CPVT have been misdiagnosed as having LQTS with normal QT intervals or concealed LQTS, which indicates the critical importance of properly distinguishing between CPVT and LQTS at the clinical level, because risk assessments and treatment strategies of these unique disorders may vary. Similarly, some patients diag-nosed with CPVT on the basis of the presence of bidirectional ventricular tachycardia on exercise have been identified as possessing KCNJ2 mutations, which are associated with the rarely lethal Andersen-Tawil syndrome (ATS1, LQT7). 68 The misdiagnosis of Andersen-Tawil syndrome as the potentially lethal disorder CPVT may lead to a more aggressive prophylactic therapy (ie, implantation of an internal cardioverter defibrillator) than necessary. Genetic testing may provide a clear differential diagnosis between atypical LQT1 and CPVT and between CPVT and ATS1.
Specific indications for clinical genetic testing for CPVT include all patients with a suspected clinical diagnosis of CPVT and those patients with exercise-induced syncope/ cardiac arrest or near-drowning in the setting of a QTc Ͻ460 ms, along with all immediate family members of a genetically proven CPVT index case.
Brugada Syndrome
BrS is another heritable arrhythmia syndrome characterized by an ECG pattern of coved-type ST-segment elevation in the right precordial leads (V 1 through V 3 ) and an increased risk for sudden death resulting from episodes of polymorphic ventricular tachyarrhythmias. 22, 69 BrS generally is considered a disorder that involves young male adults, with arrhythmogenic manifestation first occurring at an average age of 40 years and sudden death typically occurring during sleep. However, like the previously mentioned channelopathies, its penetrance and expressivity are highly variable, ranging from entirely asymptomatic individuals to sudden cardiac death during the first year of life. In addition, idiopathic ventricular fibrillation in many cases may be clinically, genetically, and mechanistically most closely linked with BrS, 70 and progressive cardiac conduction defect is often an overlapping phenotype with BrS. 71 Although gain-of-function mutations in SCN5A cause approximately 5% to 10% of LQTS (LQT3), approximately 20% to 25% of BrS results from loss-of-function mutations in the SCN5A-encoded cardiac sodium channel (NaV1.5, BrS1; Table  3 ; Figure 8 ). In 2009, an international compendium of SCN5A mutations derived from Ͼ2000 patients referred for BrS genetic testing hosted nearly 300 distinct mutations in 438 (21%) of 2111 unrelated patients, and the mutation detection yield ranged from 11% to 28% across the 9 testing centers. 72 In 2009, Meregalli et al 73 illustrated that the SCN5A mutation type can anticipate the severity of progressive cardiac conduction defect and BrS. Their data suggest that those mutations with a more Figure 7 . Catecholaminergic polymorphic ventricular tachycardia (CPVT), a disorder of intracellular calcium handling. A, Perturbations in key components of the calcium-induced calcium release (CICR) mechanism responsible for cardiac excitation-contraction coupling are the pathogenic basis for CPVT. At the center of this mechanism is the RYR2-encoded cardiac ryanodine receptor/calcium release channel located in sarcoplasmic reticulum membrane. Mutations in RyR2 are clustered and distributed in 3 "hotspot" regions of this 4967-amino acid (AA) protein: Domain I or N-terminal domain (AA 57 to 1141), domain II or the central domain (AA 1638 to 2579), and domain III or channel region (AA 3563 to 4967). PMCA indicates plasma membrane calcium ATPase; SERCA2a, sarcoplasmic endoplasmic reticular calcium ATPase. B, Because of this clustering of mutations, a tiered strategy for genetic testing of the 105-exon RYR2 gene has been proposed. 59 C, The percent yield of RYR2 mutation detection in cases of strong CPVT, possible CPVT, and LQT1 through LQT3 gene-negative long-QT syndrome ("LQTS") referral cases manifesting with exercise-induced cardiac events. 59 deleterious loss of sodium current produce a more severe phenotype of syncope and conduction defect, which provides the first evidence for intragenotype risk stratification associated with SCN5A loss-of-function disease. Akin to LQTS, knowledge of the SCN5A mutation status may assist in the risk stratification of patients with BrS.
In addition to mutations that involve the Nav1.5 sodium channel, mutations in genes (GPD1L, 74 SCN1B, 75 and SCN3B 76 ) that modulate sodium channel function have been associated with BrS. Recently, mutations that involve the L-type calcium channel ␣-subunit (CACNA1C) and ␤-subunit (CACNB2B) have been implicated in nearly 10% of BrS cases, 77 whereas mutations in the putative ␤-subunit of the transient outward potassium channel (I to , KCNE3) have been reported as a rare cause. 78 Still, nearly two thirds of BrS remains genetically elusive.
Patients suspected of having BrS, idiopathic ventricular fibrillation, or progressive cardiac conduction defect could undergo clinical genetic testing provided that it is understood that the yield from currently available BrS genetic tests is approximately 25% to 35%. Furthermore, except for the recent association between SCN5A mutation type and clinical severity, the primary role of BrS genetic testing is diagnostic confirmation of the root cause for an index case, followed by confirmatory genetic testing of immediate family members to distinguish those needing ongoing clinical surveillance and preventative measures (www.brugadadrugs.org) from those who can be dismissed as clinically, electrocardiographically, and genetically unaffected (Figure 4 ).
Conclusions
Genomic advances have propelled cardiologists into the era of personalized genomic medicine. As novel genes are discovered, the compendium of available genetic tests will surely increase. For the 4 specific heritable cardiomyopathies/ channelopathies detailed in the present review, the bench-tobedside continuum of research from scientific discovery to translation to clinical implementation and even postimplementation test interpretation has been completed or is nearing completion. Now, with genetic testing being added to our armamentarium of diagnostic/prognostic tests, it behooves the community of cardiologists to not only be conversant in the language of genomic medicine but also to be a wise user and an even wiser interpreter of genetic test results so that wise decisions can be rendered for those patients and families being evaluated with respect to the presence or absence of one of these potentially lethal yet highly treatable genetic cardiomyopathies/channelopathies. Depicted is the linear topology of the 2016-amino acid-containing cardiac sodium channel isoform with mutation locations and their associated disorders. Circles denote missense mutations and squares represent radical mutations, including frameshift insertion/deletion mutations, in-frame insertions/deletions, nonsense mutations, and splice-site mutations.
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